MASH and MASLD are prevalent, complex diseases often accompanied by metabolic comorbidities like obesity and diabetes. GLP-1 receptor agonists, such as semaglutide, show promise in resolving NASH ...

Souza M, Al-Sharif L, Diaz I, et al. Representation of sex, race and ethnicity in mash randomised controlled trials: a systematic review and meta-analysis. Liver Int . 2025;45(4):e70029. doi:10. ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

This package is available to First Home Buyers only through our First Home Buyer Program. We will arrange the loan for you. To qualify for our First Home Buyer Program conditions of course apply ...

Hover over Tap a data point to see when it was last updated. Median values are calculated based on data over a 12 month period. Data is provided by CoreLogic. CoreLogic is a leading provider of ...

Hover over Tap a data point to see when it was last updated. Median values are calculated based on data over a 12 month period. Data is provided by CoreLogic. CoreLogic is a leading provider of ...